WO2000024869A3 - Methods for modulating cell fusion - Google Patents

Methods for modulating cell fusion Download PDF

Info

Publication number
WO2000024869A3
WO2000024869A3 PCT/US1999/024838 US9924838W WO0024869A3 WO 2000024869 A3 WO2000024869 A3 WO 2000024869A3 US 9924838 W US9924838 W US 9924838W WO 0024869 A3 WO0024869 A3 WO 0024869A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell fusion
methods
fusion
mfr
modulation
Prior art date
Application number
PCT/US1999/024838
Other languages
French (fr)
Other versions
WO2000024869A2 (en
WO2000024869A9 (en
Inventor
Agnes Vignery
Original Assignee
Univ Yale
Agnes Vignery
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale, Agnes Vignery filed Critical Univ Yale
Priority to AU12242/00A priority Critical patent/AU1224200A/en
Publication of WO2000024869A2 publication Critical patent/WO2000024869A2/en
Publication of WO2000024869A9 publication Critical patent/WO2000024869A9/en
Publication of WO2000024869A3 publication Critical patent/WO2000024869A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5055—Cells of the immune system involving macrophages
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70585—CD44

Abstract

The invention relates generally to modulation of cell fusion by altering the function and or expression of cell surface proteins. The invention relates specifically to modulation of Macrophage Fusion Receptor (MFR) or CD44 to alter cell fusion. Methods are described for identifying agents which alter cell fusion by modulating MFR or CD44. The invention includes methods which are useful in treating pathological states associated with altered cell fusion. Pathological states which may be treated by the methods of the present invention involve alterations in physiological processes underlying viral infections, bone resorption, muscle development and fertilization.
PCT/US1999/024838 1998-10-23 1999-10-22 Methods for modulating cell fusion WO2000024869A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU12242/00A AU1224200A (en) 1998-10-23 1999-10-22 Methods for modulating cell fusion

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15738798P 1998-10-23 1998-10-23
US60/157,387 1998-10-23

Publications (3)

Publication Number Publication Date
WO2000024869A2 WO2000024869A2 (en) 2000-05-04
WO2000024869A9 WO2000024869A9 (en) 2005-02-10
WO2000024869A3 true WO2000024869A3 (en) 2007-08-23

Family

ID=22563509

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/024838 WO2000024869A2 (en) 1998-10-23 1999-10-22 Methods for modulating cell fusion

Country Status (2)

Country Link
AU (1) AU1224200A (en)
WO (1) WO2000024869A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9930706D0 (en) * 1999-12-24 2000-02-16 Medical Res Council Composition for inhibiting macrophage activity
CA2988137C (en) * 2015-06-11 2021-01-26 Maria Siemionow Muscular dystrophy chimeric cells and method for treating muscular dystrophies
WO2017220989A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
EP3658589B1 (en) 2017-07-26 2023-09-27 Forty Seven, Inc. Anti-sirp-alpha antibodies and related methods
CN108567973B (en) * 2017-10-17 2021-03-19 中国科学院深圳先进技术研究院 Placenta-like chondroitin sulfate A immune composition and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804594A (en) * 1997-01-22 1998-09-08 Murad; Howard Pharmaceutical compositions and methods for improving wrinkles and other skin conditions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804594A (en) * 1997-01-22 1998-09-08 Murad; Howard Pharmaceutical compositions and methods for improving wrinkles and other skin conditions

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
KLUEG K M, PARODY T R, MUSKAVITCH M A T, AMERICAN SOCIETY FOR CELL BIOLOGY ANNUAL MEETING., XX, XX, 1 December 1997 (1997-12-01), XX, pages 413 + 01, XP002926946 *
SAGINARIO ET AL.: "Identification of an Inducible Surface Molecule Specific to Fusing Macrophages", PROC. NATL. ACAD. SCI. USA,, vol. 92, December 1995 (1995-12-01), pages 12210 - 12214, XP002926947 *
SAGINARIO ET AL.: "MFR, a Putative Receptor Mediating the Fusion of Macrophages", MOLECULAR AND CELLULAR BIOLOGY,, vol. 18, no. 11, November 1998 (1998-11-01), pages 6213 - 6223, XP002926948 *
STERLING ET AL.: "CD44 Occupancy Prevents Macrophage Multinucleation", THE JOURNAL OF CELL BIOLOGY,, vol. 143, no. 3, November 1998 (1998-11-01), pages 837 - 847, XP002926949 *
STERLING H, SAGINARIO C, VIGNERY A: "CD44 OCCUPANCY PREVENTS THE FUSION OF MACROPHAGES", AMERICAN SOCIETY FOR CELL BIOLOGY ANNUAL MEETING., XX, XX, vol. 08, 1 December 1997 (1997-12-01), XX, pages 413 + 01, XP002926945 *

Also Published As

Publication number Publication date
AU1224200A (en) 2000-05-15
WO2000024869A2 (en) 2000-05-04
WO2000024869A9 (en) 2005-02-10

Similar Documents

Publication Publication Date Title
HK1069767A1 (en) Methods for inhibiting ocular processes
EP1507005A3 (en) Antisense modulation of BCL-X expression
EE04221B1 (en) Use of estrogen in the manufacture of a medicament for the treatment of physical conditions in postmenopausal individuals
WO2001076514A3 (en) Methods and devices for treating fractured and/or diseased bone
WO2002099075A3 (en) Prmts as modifiers of the p53 pathway and methods of use
BR9911396A (en) Enzyme stabilization by means of cationic surfactants
ZA993364B (en) Novel 4-phenylpiperidines for the treatment of pruritic dermatoses.
MX2009006685A (en) Dr6 antagonists and uses thereof in treating neurological disorders.
BR9917352B1 (en) process for polymerizing ethylene and at least one or more other olefin (s) to produce ethylene / olefin interpolymer.
DK1123414T3 (en) Antisense modulation of integrin alpha 4. expression
WO2000024869A3 (en) Methods for modulating cell fusion
ATE293254T1 (en) MODULATION OF MLK (MULTIPLE LINEAGE KINASE) PROTEINS
EP1131332A4 (en) Antisense modulation of inhibitor-kappa b kinase-beta expression
EP1131107A4 (en) Antisense modulation of inhibitor-kappa b kinase-alpha expression
WO1999049038A3 (en) Human calcium-binding proteins
WO2003066821A3 (en) Molecules interacting with casl (mical) polynucleotides, polypeptides, and methods of using the same
SI1427830T1 (en) Bv8 NUCLEIC ACIDS AND POLYPEPTIDES WITH MITOGENIC ACTIVITY
EP1582224A4 (en) Method of treating biological tissue by microwave-irradiation
BR9811643A (en) Chemical bone supplementation
ATE288498T1 (en) METHODS FOR INHIBITING HELICOBACTER PYLORI
EP1255110A3 (en) Methods and products for identifying modulators of P2X7 receptor activity, and their use in the treatment of skeletal disorders
EP1363528A4 (en) Methods for diagnosing and treating heart disease
WO2004082610A3 (en) Modulation of hyaluronan and cd44 interaction and uses thereof in treating disorders
WO2002017900A9 (en) Modulators of us28 (chemokines) for treating cytomegalovirus infections
WO2003028536A3 (en) Methods for diagnosing and treating heart disease

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 2000 12242

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 09830169

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
COP Corrected version of pamphlet

Free format text: PAGES 1-13, SEQUENCE LISTING, ADDED